Literature DB >> 6746086

Decreased uptake of 3H-serotonin and endogenous content of serotonin in blood platelets in hypertensive patients.

L A Kamal, K H Le Quan-Bui, P Meyer.   

Abstract

The uptake and content of serotonin in blood platelets were studied in patients with essential hypertension and in five families in which at least one member was hypertensive. Blood was obtained from male and female normotensive volunteers and hypertensive patients who were free of medication. Lineweaver-Burk plots of 3H-serotonin uptake from both control subjects and hypertensive patients were linear, which suggested simple Michaelis-Menten uptake kinetics. The maximal uptake velocity (Vmax) in hypertensive patients was significantly lower than in control subjects (control = 41.7 +/- 3.3 pmol/min/10(8) platelets, n = 17; hypertensive = 26.6 +/- 3.0 pmol/min/10(8) platelets, n = 16; p less than 0.005). The affinity constant (Km) was slightly but significantly lower in hypertensive patients (control = 0.70 +/- 0.08 microM; hypertensive = 0.46 +/- 0.08 microM; p less than 0.05). The serotonin content in blood platelets determined by high pressure liquid chromatography with electrochemical detection was significantly lower in hypertensive patients (control = 165.0 +/- 12.9 nmol/10(11) platelets, n = 29; hypertensive = 105.9 +/- 10.4 nmol/10(11) platelets, n = 27; p less than 0.001). In the five families investigated, the lowered serotonin content was observed in some normotensive members. The reduced number of carriers of serotonin uptake and the slight decrease in the affinity constant observed in platelets of patients with essential hypertension suggest that serotonin metabolism is altered in essential hypertension and that blood platelets may be a useful model in studying the serotonergic modifications at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746086     DOI: 10.1161/01.hyp.6.4.568

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels.

Authors:  Charles P Mercado; Fusun Kilic
Journal:  Mol Interv       Date:  2010-08

Review 3.  Ageing, serotonin and ketanserin.

Authors:  A Breckenridge
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

5.  Serotonin and platelet aggregation in patients with essential hypertension compared with a normotensive control group.

Authors:  D J Stott; A R Saniabadi; G C Inglis; J Hosie; G D Lowe; S G Ball
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Impaired uptake of 5 hydroxytryptamine platelet in essential hypertension: clinical relevance.

Authors:  N Fetkovska; A Pletscher; F Ferracin; R Amstein; F R Buhler
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 7.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

8.  Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension.

Authors:  L S Malatino; B Stancanelli; G Greco; G Polizzi; G Assogna; C Zanna; G Tamburino
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

9.  Endothelin-1, nitric oxide, serotonin and high blood pressure in male adolescents.

Authors:  Gulfiia Nagimovna Aflyatumova; Razina Ramazanovna Nigmatullina; Dinara Ilgizarovna Sadykova; Mariia Dmitrievna Chibireva; Francesco Fugetto; Raffaele Serra
Journal:  Vasc Health Risk Manag       Date:  2018-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.